Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Oxurion Announces Upcoming Preclinical Presentation on THR-149 at KININ2022

24 May 2022

Leuven, BELGIUM, Boston, MA, US MAY 24, 2022 – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that an abstract evaluating the pharmacokinetic properties of THR-149 will be presented at KININ2022 to be held June 6-8, 2022 in Annecy, France. 

THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of diabetic macular edema (DME) patients showing suboptimal response to anti-VEGF therapy. Oxurion is studying THR-149 in Part B of its two-part Phase 2 KALAHARI trial evaluating THR-149 for the treatment of DME. 

Details of the presentation: 

TITLE: Pharmacokinetics of THR-149, a potent and specific plasma kallikrein bicyclic peptide inhibitor 

PRESENTER: Marc Vanhove, Head, Biochemistry & in vitro Pharmacology, Oxurion NV 

PRESENTATION DATE AND TIME: Tuesday, June 7, 2022, 2.30 p.m. CET 

Press release attachment: 
Tags: 
Event; THR-149